Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Overvåking av respons på neoadjuvant kjemoterapi ved HER2 negativ brystkreft ved bruk av høyhastighets MR-spektroskopisk avbildning

13. november 2026 oppdatert av: New Mexico Cancer Research Alliance

Overvåking av respons på neoadjuvant kjemoterapi (NAC) ved HER2 negativ brystkreft (HNBC) ved bruk av høyhastighets MR-spektroskopisk avbildning (MRSI)

The study will assess whether changes in total choline concentration [tCho] during neoadjuvant chemotherapy (NAC) are predictive of pathologic complete response (pCR) in patients with HER2 negative breast cancer (HNBC) appropriate for NAC, and compare these findings with dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). The objective is to assess the predictive value of changes in the concentration and spatial extent of tCho within the tumor during NAC.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Detaljert beskrivelse

The primary objective of the study is to assess the correlation of serial high-speed MRSI of [tCho] with pCR following NAC in women with HNBC. The endpoint is the pCR.

Hypothesis 1: Changes in [tCho] early during NAC (from 24 hours after the start of the first cycle until the start of the 2nd cycle of NAC) are predictive of pathologic response (using quantitative metrics of Residual Cancer Burden (RCB)1 and/or CPS+EG score 2 and radiologic response (change in lesion size on DCE-MRI).

Hypothesis 2: Decreases in [tCho] within the tumor precede decreases in tumor volume on DCE-MRI, thus enabling earlier discrimination between responders from non-responders. The primary objective of the study is to assess the correlation of serial high-speed magnetic resonance spectroscopic imaging (MRSI) of [tCho] with pCR following NAC for HNBC. The secondary objective is to compare the time course of [tCho] on serial high-speed MRSI and tumor volume on serial DCE-MRI for predicting early NAC treatment response in HNBC.

Subjects' participation will start approximately 2 weeks before initiation of neoadjuvant therapy and end after surgery.

Patients will undergo up to 5 MRI scans in total as 2 are clinical MRIs and 3 are research scans. The clinical pretreatment MRI scan and a post treatment MRI scan are standard and will be ordered at the discretion of the treating provider.The post treatment MRI is done after clinical response and before surgery. This helps guide the surgeon about what amount of tissue should be removed at surgery. The minimum time between clinical and research MRI scans is 24 hours.

The 3 research MRIs will be performed on a 3T Siemens scanner equipped with 16 channel Hologic breast coil. Breast anatomy will be imaged using a bilateral localizer, an axial T 2-weighted turbo-spin-echo scan, and a fat-suppressed T1-weighted sagittal gradient echo scan. Dynamic non-fat-suppressed T1-weighted axial 3D GRE scans are collected before and with 20s delay at four time points after Gd-HP-DO3A administration (total scan time: 7.5 min). Subtraction images are created using the pre-contrast image as the mask. A diffusion weighted multi-slice EPI scan will be performed to compute apparent diffusion coefficient (ADC) maps online (total scan time: 3:14 min). An axial low-resolution multi-slice multi-echo gradient echo scan will be performed to compute field maps for slice and laterality specific auto-shimming. Spectroscopic imaging will be performed using 3D PEPSI.

The MR measurement protocol will be performed at 3 time points: (1) prior to treatment typically several days before NAC (ideally 24h before NAC) (MRSI, DW-MRI, DCE-MRI), (2) 20-52 hours after the beginning of the first cycle of NAC (MRSI, DW-MRI), and (3) between the first and second cycle of NAC (MRSI, DW-MRI, DCE-MRI).

Surgery will be performed within 3 to 12 weeks of last chemotherapy. RCB will be obtained from the final pathologic findings.

Studietype

Observasjonsmessig

Registrering (Antatt)

30

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • New Mexico
      • Albuquerque, New Mexico, Forente stater, 87131
        • University of New Mexico Comprehensive Cancer Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Eligible female breast cancer patients receiving treatment at the University of New Mexico Comprehensive Cancer Center.

Beskrivelse

Inclusion Criteria:

  • Have a biopsy proven HER2 negative (by IHC or FISH) breast cancer per standard clinical criteria (per ASCO-CAP guidelines). Although patients with hormone-receptor positive (ER+ and/or PR+) disease will be included, patients with tumor features indicative of luminal A intrinsic sub-type will be excluded from this study. Excluding features are:

    • Patients with Grade 1 breast cancers, as assessed by local standard criteria, will be excluded from participation.
    • Patients with strongly ER AND PR positive breast cancer, defined as >75% positive staging for BOTH markers by IHC, will be excluded from participation.
  • Stage of disease that is appropriate for standard NAC (any combination of T2 to T4, N0 to N3 that would comprise stage IIA to IIIB disease). Patients with inflammatory carcinoma or stage IIIC disease who are deemed inoperable at the outset, but appropriate for NAC are excluded in this study since there is no guarantee they can be converted to operability following NAC; thus precluding assessment of pCR.

  • Medically fit for NAC as per good clinical practice and per the treating physician's judgment.

  • Age > or = to 18 years AND able to provide informed consent.

  • Women of childbearing potential must be willing and able to use effective means of contraception. A female of childbearing potential is any woman who has not undergone a hysterectomy or bilateral oophorectomy or has not had menses at any time in the preceding 12 consecutive months.

  • Able to undergo standard clinical MRI exams PLUS additional 30 minutes longer (total scan time is 50 to 60 minutes).

Exclusion Criteria:

  • Pregnant or lactating women.
  • Body contains foreign items posing an issue of MRI safety, such as intra-ocular metallic foreign bodies, MRI incompatible devices such as pacemakers and cochlear implants, and other MRI incompatible devices.
  • Obesity (Body Mass Index [BMI] > 40) or inability to fit into the standard MRI gantry.
  • Suffer from back pain, claustrophobia, seizures, panic disorder and/or other medical disorders severe enough that would prevent them from completing a standard clinical MRI study (30 min) + 30 mins for the research scans. If applicable, patients may take a mild anxiolytic (e.g., lorazepam) if deemed appropriate by their treating physician.
  • Patients with stage IV disease (gross metastasis or documented M1 disease) and stage of disease excluded above.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Assess the correlation of serial high-speed MRSI of [tCho] with pCR following NAC
Tidsramme: Patient will begin participation 2 weeks prior to initiation of NAC and will complete participation at the time of surgery, estimated to be 4-6 months total participation duration.

In this study changes in total choline concentration [tCho] during neoadjuvant chemotherapy (NAC) will be evaluated by performing a high-speed magnetic resonance spectroscopic imaging (MRSI) at baseline prior to first cycle NAC, after first cycle NAC, and prior to second cycle NAC.

Patient will begin participation 2 weeks prior to initiation of NAC and will complete participation at the time of surgery, estimated to be 4-6 months total participation duration.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Assess the correlation of serial high-speed MRSI of [tCho] with response to NAC
Tidsramme: Patient will begin participation 2 weeks prior to initiation of NAC and will complete participation at the time of surgery, estimated to be 4-6 months total participation duration.

The endpoint is response as assessed by the validated quantitative metrics of Residual Cancer Burden (RCB) and/or CPS+EG score.

Patient will begin participation 2 weeks prior to initiation of NAC and will complete participation at the time of surgery, estimated to be 4-6 months total participation duration.
Compare the time course of [tCho] on serial high-speed MRSI and tumor volume on serial DCE-MRI for predicting early NAC treatment response
Tidsramme: Patient will begin participation 2 weeks prior to initiation of NAC and will complete participation at the time of surgery, estimated to be 4-6 months total participation duration.

Outcome measured will be total choline concentration [tCho] as assessed via serial high-speed magnetic resonance spectroscopic imaging (MRSI) .

Patient will begin participation 2 weeks prior to initiation of NAC and will complete participation at the time of surgery, estimated to be 4-6 months total participation duration.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Stefan Posse, PhD, University of New Mexico Comprehensive Cancer Center

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

16. april 2018

Primær fullføring (Faktiske)

22. januar 2020

Studiet fullført (Antatt)

31. desember 2027

Datoer for studieregistrering

Først innsendt

30. mai 2018

Først innsendt som oppfylte QC-kriteriene

13. juni 2018

Først lagt ut (Faktiske)

26. juni 2018

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

13. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • INST 1607

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere